Live Earnings Conference Call: Vaxart will host a live Q1 2026 earnings call on May 8, 2026 at 4:30PM ET. Follow this link to get details and listen to Vaxart's Q1 2026 earnings call when it goes live. Get details. OTCMKTS:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.70 -0.04 (-5.41%) As of 02:47 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesOwnershipSEC FilingsBuy This Stock About Vaxart Stock (OTCMKTS:VXRT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vaxart alerts:Sign Up Key Stats Today's Range$0.67▼$0.7550-Day Range$0.60▼$0.8052-Week Range$0.26▼$0.84Volume612,024 shsAverage Volume694,339 shsMarket Capitalization$169.38 millionP/E Ratio11.67Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vaxart, Inc. is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics. The company’s pipeline includes multiple vaccine candidates in various stages of development. Among these are an oral tablet for norovirus, an oral influenza vaccine, and VXA-CoV2-1, an oral COVID-19 vaccine candidate. Vaxart has reported data from Phase I and Phase II clinical trials demonstrating favorable safety profiles and immune responses that support further clinical evaluation. In addition to its lead programs, Vaxart is exploring applications of its platform for prophylactic and therapeutic vaccines against other respiratory and enteric pathogens. Headquartered in South San Francisco, California, Vaxart collaborates with academic institutions and government agencies to advance its oral vaccine technology. The company’s management team brings together experienced professionals in vaccine R&D, regulatory affairs, and commercial strategy, guiding Vaxart through clinical and regulatory milestones. By focusing on ease of administration and global distribution, Vaxart seeks to address unmet needs in vaccine access and public health preparedness. AI Generated. May Contain Errors. Read More Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VXRT Stock News HeadlinesVaxart Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7 at 9:06 PM | finance.yahoo.comVaxart Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7 at 4:05 PM | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 8 at 1:00 AM | InvestorPlace (Ad)Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ETMay 1, 2026 | finance.yahoo.comVaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ETMay 1, 2026 | globenewswire.comVaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of DirectorsApril 23, 2026 | finance.yahoo.comVaxart Adds Veteran Biotech Leader to BoardApril 23, 2026 | tipranks.comVaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors to Enhance Clinical Development and Regulatory ExpertiseApril 23, 2026 | quiverquant.comQSee More Headlines VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.3464 at the beginning of 2026. Since then, VXRT stock has increased by 97.0% and is now trading at $0.6825. How were Vaxart's earnings last quarter? Vaxart, Inc. (OTCMKTS:VXRT) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.02. The biotechnology company earned $39.23 million during the quarter, compared to the consensus estimate of $65.50 million. Vaxart had a trailing twelve-month return on equity of 33.83% and a net margin of 6.88%. When did Vaxart's stock split? Vaxart shares reverse split on Wednesday, February 14th 2018.The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA). Company Calendar Last Earnings5/07/2026Today5/08/2026Next Earnings (Estimated)5/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:VXRT Previous SymbolNASDAQ:NABI CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees120Year Founded2004Profitability EPS (Trailing Twelve Months)$0.15 Trailing P/E Ratio11.67 Forward P/E RatioN/A P/E GrowthN/ANet Income$16.33 million Net Margins6.88% Pretax Margin7.08% Return on Equity33.83% Return on Assets9.10% Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.57 Sales & Book Value Annual Sales$47.40 million Price / Sales3.57 Cash Flow$0.10 per share Price / Cash Flow7.28 Book Value$0.37 per share Price / Book1.89Miscellaneous Outstanding Shares241,973,000Free Float235,198,000Market Cap$169.38 million OptionableNo Data Beta1.18 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:VXRT) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredElon Musk Might Be Getting Your Retirement MoneyWhen the SpaceX IPO lands, fund managers may rebalance your 401(k) to chase it - and they don't need your perm...Americas Gold Company | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
